Kyowa Hakko launches Immuse immune activator ingredient

October 1, 2020

Kyowa Hakko Bio Co. Ltd. and parent company Kirin Holdings Co. Ltd. launched Immuse, a unique patented strain of Lactococcus lactis characterized as a heat-killed lactic acid bacteria (paraprobiotic) that supports the immune system.

Kyowa Hakko Bio Co. Ltd. (New York City, NY) and parent company Kirin Holdings Co. Ltd. launched Immuse, a unique patented strain of Lactococcus lactis characterized as a heat-killed lactic acid bacteria (paraprobiotic) that supports the immune system. It activates plasmacytoid dendritic cells (pDC), which has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, providing broad range immune support. 

“A strong immune system is critical for good health, and Immuse is a unique dietary supplement ingredient that offers broad range immune support,” said Elyse Lovett, MS, MBA, senior marketing manager at Kyowa Hakko U.S.A. Inc., in a press release. “With more consumers looking for ways to enhance their immune system and stay healthy throughout the year, we are confident that Immuse, backed by both Kirin Holdings and Kyowa Hakko, will open new doors for consumers desiring a novel option for brand range immune support.”

Immuse is supported by 10 human trials—eight efficacy, two safety studies. A series of safety data including in vitro, in vivo, and in human have been collected. It is stable in a wide variety of applications including tablets, capsules, and gummy formulations.